NEW MJ NEWS

Sundial Growers Inc to Host Earnings Call

Sundial Growers Inc (NASDAQ:SNDL) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on November 12, 2020 at 10:30 AM Eastern Time.

To listen to the event live or access a replay of the call – visit
https://www.investornetwork.com/event/presentation/70999

To receive updates for this company you can register by emailing info@investornetwork.com or by clicking get investment info from the company’s profile.

– ADVERTISEMENT –

About Investor Network

Investor Network (IN) is a financial content community, serving millions of unique investors market information, earnings, commentary and news on what’s trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.

SOURCE: Investor Network

View source version on accesswire.com:
https://www.accesswire.com/616219/Sundial-Growers-Inc-to-Host-Earnings-Call


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Tilray, Inc. (TLRY) Receives the First and Only Market Authorization to Offer Medical Cannabis Products in Portugal

Tilray® Receives the First and Only Market Authorization to Offer Medical Cannabis…

American Premium Water Corporation (HIPH) Celebrates Passage of 2018 Farm Bill Formally Legalizing Hemp in the US

American Premium Water Corp. (HIPH) Celebrates Passage of 2018 Farm Bill Formally…

Canopy Growth Corporation (WEED.TO) (CGC) to Acquire Assets of Colorado-Based Hemp Innovator Ebbu

Canopy Growth to Acquire Assets of Colorado-Based Hemp Innovator Ebbu Canopy Growth…

$OXIS Begins Enrolling and Treating Patients in FDA Phase 1/Phase 2 Clinical Trial

Oxis Begins Enrolling and Treating Patients in FDA Phase 1/Phase 2 Clinical…